Prognostic factors in ductal pancreatic cancer

1998 ◽  
Vol 383 (2) ◽  
pp. 129 ◽  
Author(s):  
C. J. Yeo ◽  
J. L. Cameron
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Ductal Pancreatic Cancer

scholarly journals Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

2020 ◽  
Author(s):  
Masashi Sawada ◽  
Akiyoshi Kasuga ◽  
Takafumi Mie ◽  
Takaaki Furukawa ◽  
Takanobu Taniguchi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Prognostic Model ◽  
Prognostic Score ◽  
Objective Response ◽  
Metastatic Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Abstract Background There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). This study aimed to evaluate the efficacy and tolerability of the modified FOLFIRINOX (mFFX) as a second-line therapy for MPC and investigate prognostic factors for survival. Methods From 2015–2019, we retrospectively reviewed the medical records of patients receiving mFFX for MPC after failure of GnP therapy. Patients were treated every 2 weeks with mFFX (intravenous oxaliplatin 85 mg/m 2 , intravenous irinotecan 150 mg/m 2 , and continuous infusion of 5-fluorouracil 2,400 mg/m 2 for 46 hours without bolus infusion) until disease progression, patient refusal, or unacceptable toxicity. Results In total, 104 patients received mFFX. The median overall survival (OS) was 7.0 months (95% confidence interval [CI]: 6.2-9.8) and the progression-free survival (PFS) 3.9 months (95% CI 2.8-5.0). The objective response rate was 10.6% and the disease control rate 56.7%. The median relative dose intensities of oxaliplatin, irinotecan, and infusional 5-FU were 80.0% (range 21.5-100%), 77.2% (range 38.1-100%), and 85.9% (range 36.9-100%), respectively. Grade 3-4 toxicities were reported in 57 patients (54.8%), including neutropenia, leukopenia, anemia, febrile neutropenia, and peripheral sensory neuropathy. Glasgow prognostic score and carcinoembryonic antigen level were independently associated with survival. Our prognostic model using these parameters could classify the patients into good (n = 38), intermediate (n = 47), and poor (n = 19) prognostic groups. The median OS and PFS time was 14.7 (95% CI 7.6-16.3) and 7.6 months (95% CI 4.1-10.5) for the good prognostic factors, 6.5 (95% CI 5.5-10.0) and 3.6 months (95% CI 2.7-4.8) for the intermediate prognostic factors and 5.0 (95% CI 2.9-6.6) and 1.7 months (95% CI 0.9-4.3) for the poor prognostic factors, respectively. Conclusions The mFFX showed to be a tolerable second-line treatment for MPC after GnP failure. Our prognostic model might be useful for deciding whether mFFX is indicated in this setting.

scholarly journals Promoting Effect of a High-Fat/High-Protein Diet in DMBA-Induced Ductal Pancreatic Cancer in Rats

2001 ◽  
Vol 233 (5) ◽  
pp. 688-695 ◽  
Author(s):  
Kaspar Z’graggen ◽  
Andrew L. Warshaw ◽  
Jens Werner ◽  
Fiona Graeme-Cook ◽  
Ramon E. Jimenez ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Protein Diet ◽  
High Protein ◽  
Protein Diet ◽  
High Fat ◽  
Promoting Effect ◽  
Ductal Pancreatic Cancer

scholarly journals Prognostic Factors in Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine: A Retrospective Analysis

2014 ◽  
Vol 40 (12) ◽  
pp. 734-741 ◽  
Author(s):  
Masahiro Hatori ◽  
Daiki Tsuji ◽  
Keisei Taku ◽  
Takashi Daimon ◽  
Mana Kamezato ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Unresectable Pancreatic Cancer

scholarly journals The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors

Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 536
Author(s):  
Katarzyna Malarz ◽  
Jacek Mularski ◽  
Marcin Pacholczyk ◽  
Robert Musiol
Keyword(s):  
Pancreatic Cancer ◽  
Bile Duct ◽  
Kinase Activity ◽  
Lung Cancers ◽  
Normal Product ◽  
Idh1 R132h ◽  
Wide Range ◽  
Receptor Kinases ◽  
The Status ◽  
Ductal Pancreatic Cancer

Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among others. Mutation R132H, which changes the functionality of an enzyme to produce mutagenic 2-hydroxyglutarate instead of a normal product, is particularly important in this field. A series of inhibitors were described for these enzymes of which ivosidenib was the first to be approved for treating leukemia and bile duct cancers in 2018. Here, we investigated the polypharmacological landscape of the activity for known sulfamoyl derivatives that are inhibitors, which are selective towards IDH1 R132H. These compounds appeared to be effective inhibitors of several non-receptor kinases at a similar level as imatinib and axitinib. The antiproliferative activity of these compounds against a panel of cancer cells was tested and is explained based on the relative expression levels of the investigated proteins. The multitargeted activity of these compounds makes them valuable agents against a wide range of cancers, regardless of the status of IDH1.

scholarly journals Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e4893 ◽  
Author(s):  
Shuisheng Zhang ◽  
Xiaozhun Huang ◽  
Yuan Tian ◽  
Saderbieke Aimaiti ◽  
Jianwei Zhang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cohort Study ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Distant Metastasis ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Clinicopathologic Characteristics ◽  
Treatment Protocols ◽  
Laboratory Parameters

Objectives The prognosis of people with pancreatic cancer is extremely unfavorable. However, the prognostic factors remain largely undefined. We aimed to perform comprehensive analyses of clinicopathologic characteristics, laboratory parameters, and treatment protocols for exploring their role as prognostic factors of pancreatic cancer. Methods Patients diagnosed with pancreatic cancer and hospitalized at the China National Cancer Center between April 2006 and May 2016 were enrolled in this retrospective cohort study. Clinicopathologic characteristics, laboratory parameters, and treatment protocols were compared among patients at different stages of the disease. The association between these factors and overall survival (OS) was analyzed using the Kaplan–Meier method and Cox proportional hazards model. Results The present study included 1,433 consecutive patients with pancreatic cancer. Median OS was 10.6 months (95% confidence interval [CI] 9.8–11.3 months), with 1-, 3-, and 5-year survival rates of 43.7%, 14.8%, and 8.8%, respectively. Cox multivariate analysis findings identified the following factors as independent predictors of OS: gender (female vs male, hazard ratio 0.72, 95% CI [0.54–0.95]); elevated total bilirubin (TBil; 1.82, 1.34–2.47); elevated carbohydrate antigen 19-9 (CA19-9; 1.72, 1.17–2.54); tumor being located in pancreatic body and tail (1.52, 1.10–2.10); advanced T stage (T3-4 vs T1-2, 1.62, 1.15–2.27); lymph node metastasis (1.57, 1.20–2.07); distant metastasis (1.59, 1.12–2.27); the presence of surgical resection (0.53, 0.34–0.81); and the presence of systemic chemotherapy (0.62, 0.45–0.82). Conclusions Being male, elevated TBil and carcinoembryonic antigen, tumor being located in pancreatic body and tail, advanced T stage, lymph node and distant metastasis, the absence of surgical resection, and the absence of systematic chemotherapy were associated with worse OS in patients with pancreatic cancer.

scholarly journals Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors

2018 ◽  
Vol 29 ◽  
pp. v45-v46
Author(s):  
B. Anton ◽  
F. Longo Muñoz ◽  
D. Gutierrez Abad ◽  
M. De Torres Olombrada ◽  
I. Juez Martel ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Second Line
Sign in / Sign up

Export Citation Format

Share Document